MHRA Drug Safety Update: repeat enhanced cardiovascular monitoring when restarting fingolimod (GilenyaT) after treatment interruption

Source: MHRA Area: Evidence > Medication Safety The January issue of the MHRA's Drug Safety Update has highlighted the risk of bradycardia and heart block on starting fingolimod treatment, or re-starting fingolimod after treatment interruption which can be minimised through enhanced cardiac monitoring.   The MHRA has updated its advice on enhanced cardiac monitoring on the basis of new clinical pharmacology analyses and dose titration data. Please see link below for full details.
Source: NeLM - Patient Safety - Category: Drugs & Pharmacology Source Type: news